Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094107 · ClinicalTrials.gov registry record · Phase 2
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
A Phase 2 study of Melanoma and Skin Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 12
- Study locations
NCT00094107 is a Phase 2 study of Melanoma and Skin Neoplasms that has completed, run by Pfizer. The registered enrollment target is 32 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (95% lower). The trial reports 12 study locations across 5 states.
The verdict
NCT00094107, a Phase 2 study of Melanoma and Skin Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a Phase 2 study being conducted at multiple centers in the United States and France. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that has been treated with no more than 1 prior treatment for metastatic disease (prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease). The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic melanoma as shown by the number of patients in the study who experience significant and durable tumor shrinkage.
Conditions Studied
Interventions
- DRUG Axitinib [AG-013736]
Study Locations (12)
Pennsylvania
- Pfizer Investigational Site - Clairton
- Pfizer Investigational Site - Greensburg
- Pfizer Investigational Site - Johnstown
- Pfizer Investigational Site - Pittsburgh
- Pfizer Investigational Site - Pittsburgh
- Pfizer Investigational Site - Wexford
Massachusetts
- Pfizer Investigational Site - Boston
- Pfizer Investigational Site - Boston
- Pfizer Investigational Site - Boston
California
- Pfizer Investigational Site - Orange
Florida
- Pfizer Investigational Site - Miami Beach
Other
- Pfizer Investigational Site - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00094107
The ClinicalTrials.gov registry entry for NCT00094107 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (95% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Axitinib [AG-013736] is the first listed.
NCT00094107 reports 12 study locations spanning 5 distinct geographic areas - top geographies include Pennsylvania, Massachusetts, California.
Frequently Asked Questions
What is clinical trial NCT00094107 about?
NCT00094107 is a clinical study titled "Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma". This is a Phase 2 study being conducted at multiple centers in the United States and France. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that has been treated with no more than 1 prior treatment for me...
What is the current status of trial NCT00094107?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2004-12. Estimated completion is 2008-04.
What conditions does trial NCT00094107 study?
This clinical trial studies the following conditions: Melanoma, Skin Neoplasms.
What interventions are being tested in trial NCT00094107?
The interventions under investigation include: Axitinib [AG-013736] (DRUG).
Who is sponsoring clinical trial NCT00094107?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00094107 being conducted?
This trial has 12 study locations across California, Florida, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.